RNS Number : 5594U
Santander UK Plc
26 February 2026

AMENDED FINAL TERMS

Santander UK plc (the "Issuer")

This notice relates to the following securities (the "**Securities**") to be issued by the Issuer on 28 April 2026 under its Structured Note and Certificate Programme:

Series 1314	**ISIN: XS3254389326**

The Issuer hereby gives notice that the Final Terms dated 19 January 2026 in respect of the Securities (the "**Original Final Terms**") are amended and restated by a new set of Final Terms dated 25 February 2026 (the "**Amended Final Terms**"). The Amended Final Terms replace the Original Final Terms.

To view a form of the Amended Final Terms showing the changes made to the Original Final Terms, please click on the link below. The Amended Final Terms will also be available on the Issuer's website at https://www.santander.co.uk/about-santander/investor-relations/santander-uk-structured-note-and-certificate-programme.

http://www.rns-pdf.londonstockexchange.com/rns/5594U_1-2026-2-26.pdf

For further information, please contact:

Structured Notes Desk

Tel: +44 (0) 20 7756 7000 or structurednotesafm@santander.co.uk

DISCLAIMER - INTENDED ADDRESSEES

Please note that the information contained in the Base Prospectus and the Amended Final Terms may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Prospectus and/or the Amended Final Terms) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Base Prospectus and/or the Amended Final Terms is not addressed. Prior to relying on the information contained in the Base Prospectus and/or the Amended Final Terms, you must ascertain from the Base Prospectus and/or the Amended Final Terms whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirement.

The Amended Final Terms referenced herein does not constitute an offer of securities for sale in the United States. The securities described herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "**Securities Act**"), or under any relevant securities laws of any state of the United States of America, and may not be offered or sold to U.S. persons or to persons within the United States of America, except pursuant to an exemption from the Securities Act.

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further

information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

PFTDZGZZGVFGVZM